Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enveric Biosciences Inc (NQ: ENVB )

0.9499 +0.0599 (+6.73%)
Streaming Delayed Price Updated: 2:50 PM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Enveric Biosciences Inc

< Previous 1 2 3 Next >
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
From Enveric Biosciences
Via Business Wire
Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
From Enveric Biosciences
Via Business Wire
5 Biotech stocks tapping into unmet mental health treatment needs
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments. 
Via MarketBeat
Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences to Present at the Centurion One 5th Global Summit
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs
From Enveric Biosciences
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.